A safety evaluation of current medications for adult women with the polycystic ovarian syndrome not pursuing pregnancy. Issue 12 (1st December 2020)

• Record Type: Journal Article
• Authors: Luque-Ramírez, Manuel; Ortiz-Flores, Andrés E.; Nattero-Chávez, Lia; Escobar-Morreale, Héctor F.
• Is Part Of: Expert opinion on drug safety. Volume 19:Issue 12(2020)
• Page Start: 1559
• Page End: 1576
• Publication Date: 2020-12-01
• Subjects: Antiandrogens -- cardiovascular risk -- combined oral contraceptives -- metformin -- polycystic ovary syndrome -- safety -- side effects -- venous thromboembolism; Drugs -- Side effects -- Periodicals; Drugs -- Toxicology -- Periodicals; Chemotherapy -- Periodicals; 615.704
• DOI: 10.1080/14740338.2020.1839409
• Languages: English
• ISSNs: 1474-0338

Abstract

ABSTRACT: Introduction: The polycystic ovary syndrome (PCOS) is a very prevalent disorder in premenopausal women. Cardiovascular risk factors cluster in these patients, raising concern about the safety of the drugs commonly used to ameliorate symptoms of androgen excess in in this population at risk of cardiovascular morbidity. Areas covered: This review summarizes the clinical efficacy and safety profiles of drugs commonly used for the management of hyperandrogenic symptoms and endometrial protection in adult women with PCOS who do not seek pregnancy. Expert opinion: Antiandrogenic drugs usually used in adult women with PCOS carry a low risk of severe side effects. In spite of the cardiovascular risk profile of women with PCOS, and that individualized risk assessment is of paramount importance, there is no solid evidence supporting that the use of combined oral contraceptives in these women increases the risk of cardiovascular or thromboembolic events compared with the general population. However, virtually all these drugs are used in an off-label fashion. Large, high-quality studies addressing the long-term safety of pharmacological treatments in women with PCOS are definitely needed.